As employers grapple with including GLP-1s in their benefits packages, they face a complex decision that boils down to two main factors: human resources and finance. On one side, there's the potential ...

RA was well tolerated in the Phase I trial. Now MBX is planning a Phase II trial in post-bariatric hypoglycaemia patients.

This is the beginning of a revolution, and how you engage and how you attack it is going to really set the stage for your ...

Recent market research reveals that glucagon-like peptide-1 (GLP-1) injections are set to dominate the obesity treatment ...

The study showed diabetic patients taking GLP-1 drugs, such as semaglutide and tirzepatide, faced significantly lower risks of 30-day readmission, wound re-opening and hematoma after surgery, compared ...

New findings provide industry leaders with actionable insights to develop personalized products and services that support ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...

Viking Therapeutics (VKTX) announced the initiation of a Phase 2 clinical trial of the oral tablet formulation of VK2735, the company’s dual ...

A range of GLP-1 weight loss drugs are currently on the market. What are they, what do they do, and where are they available?

The New York company is hoping to enter the GLP-1RA space with its newest offering requiring dosing every month over ...

For adults with overweight or obesity without diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are efficacious ...

Phase 1 results support proceeding to Phase 2 in patients with post-bariatric hypoglycemia (PBH),which is expected to begin in 2H 2025Phase 1 ...